Establish a consortium of genetics and genomics experts to develop and execute a large scale sequencing project to analyze the genomes of a large number of well characterized individuals including multi-ethnic subjects using next generation sequencing approaches; identify a broad range of AD and ADRD risk and protective gene variants in subjects with age-related dementias. These efforts should incorporate diverse sample sets (including racial/ethnic groups, the oldest old, and other well characterized individuals from epidemiological/observational studies) and include replication studies and data harmonization.
- Identification of new risk and protective alleles for late onset AD and related dementias that lead to the identification of at least one novel therapeutic approach, drug target or pathway for prevention.
- Research Implementation Area
- Drug Development - Novel Targets
- PAR-14-070: Limited Competition: Renewal of, and Revisions to, the Alzheimer's Disease Genetics Consortium (U01)
- PAR-18-889: Limited Competition: Renewal of, and Revisions to, the Alzheimer's Disease Genetics Consortium (U01)
- PAR-17-214: Limited Competition: Analysis of Data from NIA's Alzheimer's Disease Sequencing Project Follow-Up Study (U01)
- PAR-19-288: Limited Competition: NIA Genome Center for Alzheimer's Disease (GCAD) (U54 Clinical Trial Not Allowed). (Reissue of RFA-AG-16-001)
Research Programs and Resources
- NIA Alzheimer’s Disease Genetics Portfolio
- Alzheimer’s Disease Genetics Consortium (ADGC)
- Alzheimer’s Disease Sequencing Project (ADSP)